Raphael Pharmaceutical (RAPH) Accumulated Expenses (2020 - 2026)

Raphael Pharmaceutical has disclosed Accumulated Expenses across 7 years of filings, most recently posting $539000.0 for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 13.95% year-over-year to $539000.0; the TTM figure through Jun 2026 stood at $539000.0 (up 13.95% YoY), while the FY2025 annual figure was $506000.0, up 1.2% from the prior year.
• Accumulated Expenses came in at $539000.0 for Q2 2026 at Raphael Pharmaceutical, up from $506000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $539000.0 in Q2 2026 to a low of $64000.0 in Q2 2022.
• Average Accumulated Expenses over 5 years is $328647.1, with a median of $392000.0 recorded in 2024.
• Year-over-year, Accumulated Expenses slumped 58.04% in 2023 and soared 431.91% in 2024.
• Over 5 years, Accumulated Expenses stood at $224000.0 in 2022, then slumped by 58.04% to $94000.0 in 2023, then soared by 431.91% to $500000.0 in 2024, then advanced by 1.2% to $506000.0 in 2025, then increased by 6.52% to $539000.0 in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $539000.0 in Q2 2026, $506000.0 in Q4 2025, and $475000.0 in Q3 2025.